Antibe Therapeutics Inc. (OTCMKTS: ATBPD) is a clinical-stage biopharmaceutical company headquartered in Toronto, Canada, dedicated to developing safer and more effective treatments for pain and inflammation. The company’s research platform centers on hydrogen sulfide-releasing non‐steroidal anti‐inflammatory drugs (NSAIDs), designed to provide pain relief while reducing gastrointestinal and cardiovascular side effects commonly associated with traditional NSAIDs.
Antibe’s lead product candidate, otenaproxesul (ATB-346), is a hydrogen sulfide–releasing derivative of naproxen that has completed multiple Phase II trials in patients with osteoarthritis pain and is progressing toward pivotal studies. In addition to ATB-346, the company maintains a preclinical pipeline of novel compounds targeting inflammatory pathways, underscoring its commitment to addressing unmet needs in chronic pain management.
Founded in 2010, Antibe has established collaborations with clinical research organizations across North America and Europe to advance its development programs. The company’s executive team is led by President and Chief Executive Officer Mark S. Collins, whose background spans pharmaceutical development and corporate leadership. Antibe’s board and management combine scientific expertise with commercial experience, positioning the company to navigate regulatory pathways and prepare for potential product commercialization.
Antibe conducts clinical operations primarily in the United States, Canada and selected European markets, leveraging external partnerships to facilitate patient recruitment and regulatory filings. With a focus on rigorous clinical validation, the company aims to bring its novel NSAID candidates through late-stage trials and into the marketplace, addressing the global burden of pain and improving patient safety profiles.
AI Generated. May Contain Errors.
